Computational design of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)-Targeted Oncolytic Virus Therapy to In-hibit Angiogenesis in Non-Small Cell Lung Cancer

This study computationally identifies a high-affinity VEGFR2-binding Fab and models its integration into an engineered oncolytic virus to block angiogenesis and enhance targeted therapy for Non-Small Cell Lung Cancer.

Posted by buchanle on Friday, June 12th, 2026 in May 2026, Non-Small Cell Lung Cancer, Oncolytic Cancer, Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)

Read more